[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"exocrine-pancreatic-insufficiency\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:exocrine-pancreatic-insufficiency":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,41,69,95,123,146,205],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100552751","phase-4-pancreatic-enzyme-replacement-therapy-for-acute-pancreatitis-associated-exocrine-pancreatic-insufficiency-100552751",false,"NCT06477159","Pancreatic Enzyme Replacement Therapy for Acute Pancreatitis-Associated Exocrine Pancreatic Insufficiency","Pancreatic Enzyme Replacement Therapy for Acute Pancreatitis-Associated Exocrine Pancreatic Insufficiency: the PERT-AP Trial","PERT-AP","Inclusion Criteria:\n\n1. Adult patients of age 18 or older, able to provide informed consent and follow all study procedures.\n2. Stable outpatient up to 12 months following an acute pancreatitis episode and has EPI based on an FE-1 \\\u003C 200 µg\u002Fg stool obtained within 3 months prior to baseline assessment (Visit 2).\n3. Score of equal or greater 0.6 on the EPI symptom tracker at baseline Visit 2.\n4. Must be off PERT (including prescription and non-prescription enzymes) for 7 days prior to baseline Visit 2.\n5. Must have fully completed the terminal intervention for necrotizing pancreatitis (surgical or endoscopic necrosectomy or percutaneous drainage).\n6. Have a Body Weight between 40 and 120 kg (amounts to 600-1800 LU\u002Fmeal pancrelipase starting dose of pancrelipase).\n7. Women of childbearing potential must have a negative urine pregnancy test at Study Day 1 and practicing at least one protocol specified method of birth control (Section 5.2.4), starting at Study Day 1 through 30 days after last dose of pancrelipase.\n8. Females of non-childbearing potential (either postmenopausal or permanently surgically sterile as defined:\n\n   * Age \\> 55 years with no menses for 12 or more months without an alternative medical cause.\n   * Age ≤ 55 years with no menses for 12 or more months without an alternative medical cause AND an FSH level \\> 40 IU\u002FL.\n\nOR\n\n* Permanently surgical sterile (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).\n\ndo not require pregnancy testing.\n\nExclusion Criteria:\n\n1. Acute pancreatitis episode due to a pancreatic cystic neoplasm, trauma, or surgery. Post-ERCP acute pancreatitis patients can be enrolled.\n2. History of definite chronic pancreatitis defined by APA Chronic Pancreatitis Guideline.1\n3. Pancreas malignancy or other active malignancies requiring systemic treatment; treated basal cell carcinoma, and treated in-situ cervical cancer can be included.\n4. Enteropathies, and gastroenteritis that may affect FE-1 levels, e.g., Inflammatory bowel disease, Celiac Disease, viral-, bacterial-, fungal-, or parasitic gastroenteritis.\n5. Gastroparesis.\n6. Confirmed or suspected cystic tumor associated with main pancreatic duct dilation or believed to be the cause of AP (in the site-PI's judgment).\n7. Prior pancreatic surgery or GI tract surgery affecting the upper GI tract including but not limited to gastric bypass surgery, total pancreatectomy.\n8. Pregnancy or breast feeding.\n9. Patients with life expectancy of less than 6 months due to advanced chronic conditions, such as congestive heart failure or chronic obstructive pulmonary disease, or other conditions which preclude study participation by judgement of the investigator.\n10. Incarcerated individuals","ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This study aims to evaluate if a 6-month course of pancrelipase (CREON) treatment improves symptoms of exocrine pancreatic insufficiency (EPI) after an attack of acute pancreatitis. Diagnosis of EPI is measured by a fecal elastase value of \\\u003C200, and patients must have a qualifying symptom burden based on the EPI symptom tracker survey. Blood and stool will be analyzed as part of this study, and other surveys of health status will be used to track improvement of symptoms.",[27],"Exocrine Pancreatic Insufficiency","RECRUITING","2026-06-08",{"date":31,"type":32},"2026-06-10","ACTUAL",{"date":34,"type":32},"2024-02-01",{"date":36,"type":21},"2027-12-31",{"name":38,"class":39},"Ohio State University","OTHER",6,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100614920","phase-4-a-study-of-effect-of-secretin-for-in-injection-chirostim-on-pancreatic-fluid-composition-in-healthy-subjects-100614920","NCT07285863","A Study Of Effect Of Secretin For In Injection (Chirostim) On Pancreatic Fluid Composition In Healthy Subjects","An Open-Label Study On The Effects Of Human Secretin For Injection (CHIROSTIM) On Pancreatic Fluid Composition In Normal Human Volunteer Participants","Inclusion Criteria\n\n* Males or non-pregnant females\n* Age 18-80.\n* Participants must be in good health based on medical history (ASA Class 3 or below)\n* Participants must be willing and able to provide informed consent\n* Receiving an endoscopic ultrasound for a non-pancreatic indication\n\nExclusion Criteria\n\n* History of any form of pancreatitis and\u002For other pancreatic diseases (e.g. pancreatic cysts, pancreatic masses).\n* History of inflammatory bowel disease\n* History of vagotomy.\n* History of surgically altered upper gastrointestinal anatomy (e.g. gastric bypass, Billroth I\u002FII)\n* History of liver disease\n* Pregnant women or nursing mothers\n* Regular use of anticholinergics\n* \\> 2 drinks of alcohol daily\n* Smokers (cigarette)",true,"80 Years",{"count":51,"type":21},24,[24],"The purpose of this study is to collect pancreas fluid from the duodenum using the endoscopic pancreas function collection method in healthy participants after pancreatic stimulation with human secretin.",[27,55],"Chronic Pancreatitis",[57,58],"pancreatic function test","Pancreatic fluid composition","2026-04-27",{"date":61,"type":32},"2026-04-28",{"date":63,"type":32},"2026-03-11",{"date":65,"type":21},"2028-03",{"name":67,"class":39},"Mayo Clinic",1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":94},"100625127","phase-4-malabsorption-blood-test-mbt-to-determine-exocrine-pancreatic-function-and-related-quality-of-life-in-chronic-pancreatitis-100625127","NCT07418593","Malabsorption Blood Test (MBT) to Determine Exocrine Pancreatic Function and Related Quality of Life in Chronic Pancreatitis","MBT","Inclusion Criteria\n\n* ≥ 18 years of age\n* RAP (≥ 2 documented lifetime attacks with ≥ 2 of 3 acute pancreatitis criteria) OR Chronic pancreatitis (Cambridge I or II with documented history of AP OR Cambridge III or IV criteria)\n* Fecal elastase ≥ 50 within the preceding 12 months\n\nExclusion Criteria\n\n* Allergy\u002FIntolerance to PERT\u002FMBT\n* Taking medications that alter fat absorption or that supplement the fatty acids being studied (e.g. orlistat, ursodeoxycholic acid, Fatty-15 fatty acid supplement etc.)\n* Taking GLP-1 Receptor Agonist therapy\n* Fecal elastase \\\u003C50 within preceding 12 months OR pre-existing diagnosis of severe Exocrine Pancreatic Insufficiency, or ongoing steatorrhea\n* Receiving Pancreatic Enzyme Replacement Therapy for \\> 5 days within the preceding 30 days\n* Acute Pancreatitis attack (documented and meeting at least 2 of 3 criteria) within the preceding 90 days\n* History of pancreatic resection or underlying malabsorptive disease\n* Pregnant or Breast Feeding\n* Other significant medical condition as judged by Principal Investigator",{"count":77,"type":21},80,[24],"This project uses the Malabsorption Blood Test (MBT) to identify patients with recurrent acute or chronic pancreatitis who have mild to moderate exocrine pancreatic insufficiency. A subgroup of patients who have response to pancreatic enzyme replacement therapy will enter a randomized, placebo-controlled pilot clinical trial for 8 weeks to identify improvements in quality of life (QOL).",[55,81,27],"Recurrent Acute Pancreatitis",[83,84,85,27],"Malabsorption Blood Test(MBT)","Chronic pancreatitis","Recurrent Acute pancreatitis","2026-04-21",{"date":59,"type":32},{"date":89,"type":32},"2026-04-20",{"date":91,"type":21},"2028-09",{"name":93,"class":39},"Anna Evans Phillips",2,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":106,"conditions":107,"keywords":109,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":4},"100574224","exocrine-pancreatic-insufficiency-and-functional-dyspepsia-100574224","NCT06756503","Exocrine Pancreatic Insufficiency and Functional Dyspepsia","Prevalence and Clinical Characteristics of Exocrine Pancreatic Insufficiency in Patients With Functional Dyspepsia","Inclusion Criteria:\n\n* Patients over 18 years of age diagnosed with functional dyspepsia based on Rome IV criteria, who have been excluded for organic, metabolic, and medication-related causes (NSAIDs), and who test negative for H. pylori.\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Organic diseases of the digestive tract (celiac disease, inflammatory bowel diseases, neoplasms, positive for H. pylori)\n* Uncontrolled systemic diseases (diabetes mellitus, hypo- or hyperthyroidism, cancer, etc.)\n* Lack of informed consent\n* Severe psychiatric disorders, defined based on the DSM-5","65 Years",{"count":104,"type":21},65,"OBSERVATIONAL","The goal of this observational study is to learn about the prevalence of exocrine pancreatic insufficiency in patients with functional dyspepsia .\n\n. The main questions it aims to answer are: What is the prevalence of exocrine pancreatic insufficiency (EPI) in patients with functional dyspepsia? Wich are the clinical characteristics associated with (EPI) in patients with functional dyspepsia? Patients diagnosed with functional dyspepsia will undergo an evaluation of clinical symptoms and fecal elastase determination. In those with fecal elastase levels below 100 µg\u002Fg, an endoscopic ultrasound and other assessments will be performed to define the cause of exocrine pancreatic insufficiency (EPI).",[27,108],"Dyspepsia",[110,111,112],"Exocrine pancreatic insufficiency","Functional dyspepsia","Fecal elastase","NOT_YET_RECRUITING","2025-08-05",{"date":116,"type":32},"2025-08-08",{"date":118,"type":21},"2025-09-01",{"date":120,"type":21},"2026-08-01",{"name":122,"class":39},"Maria Marta Piskorz",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":102,"enrollmentInfo":130,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":132,"conditions":133,"keywords":136,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":143,"leadSponsor":145,"locationsCount":68},"100574289","fatty-liver-and-pancreatic-steatosis-100574289","NCT06757348","Fatty Liver and Pancreatic Steatosis","Association Between Fatty Liver and Pancreatic Steatosis in Patients With Metabolic Syndrome","Inclusion Criteria:\n\n* Patients over 18 years old with a diagnosis of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).\n\nExclusion Criteria:\n\n* \\- Alcohol consumption \\>20 g\u002Fday in women, \\>30 g\u002Fday in men\n* Chronic hepatitis B or C infection\n* Autoimmune liver diseases: autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis\n* Hereditary hemochromatosis\n* Wilson's disease\n* Alpha-1 antitrypsin deficiency\n* Celiac disease\n* Uncontrolled thyroid disease\n* Active or chronic infectious disease\n* Active cancer or ongoing treatment\n* Chronic renal insufficiency\n* Pregnancy\u002Flactation\n* Insufficient data\n* Patients who do not complete follow-up",{"count":131,"type":21},61,"The goal of this observational study is to determine the prevalence of pancreatic steatosis in patients with fatty liver and determine the prevalence of exocrine pancreatic insufficiency (EPI) in these patients.\n\nParticipants with fatty liver and metabolic syndrome will undergo fecal elastase measurement and endoscopic ultrasound (EUS).",[27,134,135],"Fatty Liver, Nonalcoholic","Pancreatic Steatosis",[137,138,139],"Fatty liver","Pancreatic steatosis","Metabolic syndrome",{"date":141,"type":32},"2025-08-06",{"date":118,"type":21},{"date":144,"type":21},"2026-03-01",{"name":122,"class":39},{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":154,"targetDuration":156,"studyType":105,"phases":4,"briefSummary":157,"conditions":158,"keywords":185,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":68},"100592939","shwachman-diamond-syndrome-global-patient-survey-and-partnering-platform-100592939","NCT06999954","Shwachman-Diamond Syndrome Global Patient Survey and Partnering Platform","The Shwachman-Diamond Syndrome Global Patient Survey and Partnering Platform Program (SDS-GPS Program)","SDS-GPS","Inclusion Criteria:\n\nThe Program invites patients of all ages who have a confirmed diagnosis of the below, using established diagnostic guidelines, plus their parents\u002Fcaregivers.\n\n* Patients with a confirmed Shwachman-Diamond Syndrome (SDS) diagnosis, including a genetic or clinical diagnosis. The initial focus will be on patients with a genetic diagnosis of SDS based on biallelic mutations in SBDS or EFL1.\n* Patients with a confirmed diagnosis of an SDS-like syndrome (e.g. due to mutations in DNAJC21, SRP54, or other genes that may be associated with an SDS-like syndrome in the future).\n* Patients with other heritable hematological malignancy disorders (such as RUNX1-FPD, Fanconi Anemia) and\u002For congenital neutropenias (such as ELANE neutropenia) are also eligible for inclusion.\n* Caregivers, parents, and close relatives of all patients above, including of patients alive or deceased.\n\nExclusion Criteria:\n\n● People who do not meet the above criteria.",{"count":155,"type":21},8000,"120 Years","The Shwachman-Diamond Syndrome Global Patient Survey and Collaboration Program (SDS-GPS) is an opportunity for patients and their families - from anywhere in the world - to share their experience living with SDS via a safe, secure, and convenient online platform, to\n\n* expand the understanding of SDS\n* improve the lives of people with SDS, and\n* accelerate the development of new therapies and cures for SDS.\n\nBy joining, participants will receive early access to relevant information about new clinical trials and other research opportunities (such as clinical registries) based on their profile, accelerating research and increasing clinical trial impact and recruitment success.\n\nThe platform, consent forms, and surveys are available in five languages: English, Spanish, French, German, and Italian. More languages to come.",[159,160,161,162,163,164,165,27,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184],"Shwachman-Diamond Syndrome","SDS","IBMF","Congenital Neutropenia","Heme Malignancy","Shwachman Syndrome","Inherited Bone Marrow Failure","WHIM","ELANE","SBDS Gene Mutation","EFL1 Gene Mutation","DNAJC21 Gene Mutation","SRP54 Gene Mutation","Inherited Cancer Syndrome","Inherited Cancer-Predisposing Syndrome","Neutropenia, Severe Chronic","Neutropenia Other","Neutropenia Chronic Benign","Ribosome Alteration","Ribosomopathy","Immune Deficiency","Inherited BMF Syndrome","Inherited Immunodeficiency Diseases","Cognitive Delay, Mild","Myelodysplastic Syndromes","Pancytopenia",[159,186,164,160,161,165,162,179,187,188,166,167,189,190,191,192,193,194,195],"Shwachman Diamond Syndrome","SDS-like syndrome","genetic cancer predisposition","SBDS","EFL1","SRP54","DNAJC21","severe chronic neutropenia","exocrine pancreatic insufficiency","ribosomopathy","2025-05-23",{"date":198,"type":32},"2025-05-31",{"date":200,"type":32},"2024-02-07",{"date":202,"type":21},"2088-12",{"name":204,"class":39},"Shwachman-Diamond Syndrome Alliance Inc",{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":22,"phases":215,"briefSummary":217,"conditions":218,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":68},"100447891","the-effects-of-pancreatic-enzyme-supplementation-in-critically-ill-patients-on-enteral-feeding-100447891","NCT05112328","The Effects of Pancreatic Enzyme Supplementation in Critically Ill Patients on Enteral Feeding","The Effects of Pancreatic Enzyme Supplementation in Critically Ill Patients on Enteral Feeding: Prospective Randomized Controlled Trial","PREZENT","Inclusion Criteria:\n\n* Adults 19 years and older\n* Hospitalized in the surgical\u002Fmedical intensive care unit of the Seoul National University Hospital\n* Enteral nutrition\n* Patients who consented to this study\n* Patients with risk factors for pancreatic exocrine dysfunction\n\n  * Shock (Norepinephrine)\n  * Sepsis (3 rd definition of sepsis)\n  * Diabetes\n  * Cardiac arrest\n  * hyperlactatemia serum lactate \\> 2 mmol\u002FL)\n  * Mechanical ventilation\n  * Continuous renal replacement therapy\n\nExclusion Criteria:\n\n* chronic pancreatitis\n* unresectable pancreatic cancer\n* History of pancreatectomy\n* Underlying diseases in which the effect of Exocrine pancreatic enzyme administration is difficult to show\n\n  * Inflammatory bowel disease\n  * Short bowel syndrome",{"count":214,"type":21},170,[216],"NA","Determine the effect of high-dose pancreatic enzyme supplementation on nutritional indicators and clinical course in critically ill patients undergoing enteral nutrition.",[219,220,27],"Critically Ill","Enteral Feeding","2021-11-04",{"date":223,"type":32},"2021-11-08",{"date":225,"type":32},"2021-07-07",{"date":227,"type":21},"2026-07-31",{"name":229,"class":39},"Seoul National University Hospital"]